Presentation is loading. Please wait.

Presentation is loading. Please wait.

The benefit of evolocumab treatment is consistent regardless of inflammation level HR 0.82 0.93 0.80 95%CI 0.70-0.95 0.83-1.05 0.71-0.90 ARR 1.6% 1.8%

Published byDwayne Holland Modified over 5 years ago

Similar presentations

Presentation on theme: "The benefit of evolocumab treatment is consistent regardless of inflammation level HR 0.82 0.93 0.80 95%CI 0.70-0.95 0.83-1.05 0.71-0.90 ARR 1.6% 1.8%"— Presentation transcript:

1 The benefit of evolocumab treatment is consistent regardless of inflammation level
HR 0.82 0.93 0.80 95%CI ARR 1.6% 1.8% 2.6% (*) Primary endpoint: composite of CV death, MI, stroke, hospitalization for UA, or coronary revascularization KM: Kaplan-Meier; hsCRP: high-sensitivity C-reactive protein; CV: cardiovascular; MI: myocardial infarction; UA: unstable angina; HR: hazard ratio; CI: confidence interval; ARR: absolute risk reduction. Bohula EA, et al. Circulation 2018

Download ppt "The benefit of evolocumab treatment is consistent regardless of inflammation level HR 0.82 0.93 0.80 95%CI 0.70-0.95 0.83-1.05 0.71-0.90 ARR 1.6% 1.8%"

Similar presentations

Trial profile Fox K et al. Lancet 2008;372:807-16.

Trial profile Fox K et al. Lancet 2008;372:
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:1349-57.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med. 2014 August 31. DOI:10.1056/NEJMoa1406430.

Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med August 31. DOI: /NEJMoa
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents
VBWG HPS. Lancet. 2003;361:2005-16. Gæde P et al. N Engl J Med. 2003;348:383-93. Recent statin trials: Reduction in primary outcome in patients with diabetes.

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation 20002005 and beyond Surrogate outcomes studies Large.

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
Rosuvastatin 10 mg n=2514 Placebo n=2497 2 to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:129-139.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.

Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents

Similar presentations

Ads by Google